ME20.4-SAP provides researchers with a powerful lesioning tool more specific and effective than chemical, surgical or electrolytic lesioning and is active in several species, including rabbit and primate. Intraventricular injection of ME20.4-SAP results in elimination of low affinity nerve growth factor receptor (p75NTR)-positive cells in rabbit. Tissue-directed injection in primates causes loss of p75NTR-positive neurons. Permanent and selective removal of cholinergic forebrain neurons makes an important animal model for the study of behavior, neuronal loss (e.g. Alzheimer’s disease), plasticity of other systems in response to loss, replacement therapy, and drug effects and dependence.
ME20.4-SAP is a chemical conjugate of the p75NTR monoclonal antibody and the ribosome-inactivating protein, saporin. It specifically eliminates p75NTR-positive neurons in human, primate, rabbit, raccoon, dog, cat, pig and sheep.
To eliminate p75NTR-expressing cells in mouse, use mu p75-SAP (Cat. #IT-16). To eliminate p75NTR-expressing cells in rat, use 192-IgG-SAP (Cat.#IT-01).
ME20.4-SAP is available individually (Cat. #IT-15) or as a kit (Cat. #KIT-15) which includes ME20.4-SAP and Mouse IgG-SAP (Cat. #IT-18).
keywords: P75NTR, NGFR, Alzheimer’s Disease, dementia, basal forebrain, animal model, neuronal loss, low affinity nerve growth factor, neurotrophin receptors, mesenchyme, Anti-NGFR, Anti-Nerve Growth Factor, ME20.4, p75, cholinergic forebrain neurons, Upper cervical ganglion, brain, neuroscience, rabbit, primates, CBF neurons, immunotoxin
Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts.
Ngo M, Han A, Lakatos A, Sahoo D, Hachey S, Weiskopf K, Beck A, Weissman I, Boiko A (2016) Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts. Cell Rep 16:1701-1716. doi: 10.1016/j.celrep.2016.07.004
Summary: The high rate of metastasis and recurrence among melanoma patients indicates the presence of cells within melanoma that have the ability to both initiate metastatic programs and bypass immune recognition. The authors identified CD47 as a regulator of melanoma tumor metastasis and immune evasion. The study involved antibody-mediated blockade of CD47 coupled with targeting of CD271+ melanoma cells by way of ME20.4-SAP (Cat. #IT-15). Mice bearing human melanoma tumor (M213 or M727) were randomized into four treatment groups with one of those groups receiving treatment with ME20.4-SAP. 1 ug in 50 ul volumes were injected directly into the center mass of the tumor once every 2 days. A therapeutic effect was observed where tumor metastasis in patient-derived xenografts was strongly inhibited when treated with the combination of antibody-mediated blockade of CD47 and targeted with ME20.4-SAP.
Related Products: ME20.4-SAP (Cat. #IT-15)
Cholinergic modulation of a specific memory function of prefrontal cortex.
Croxson PL, Kyriazis DA, Baxter MG (2011) Cholinergic modulation of a specific memory function of prefrontal cortex. Nat Neurosci 14(12):1510-1512. doi: 10.1038/nn.2971
Summary: The authors investigated loss of acetylcholine in the large and highly differentiated PFC's of rhesus monkeys. The monkeys received 80-92 20-ng injections of ME20.4-SAP (Cat. #IT-15) per hemisphere. Lesioned animals were severely impaired on tasks involving spatial working memory.
Related Products: ME20.4-SAP (Cat. #IT-15)
Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.
Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W (2005) Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 314(3):1274-1289. doi: 10.1124/jpet.105.086363
Related Products: ME20.4-SAP (Cat. #IT-15)
browse all references for this product | back to top
Reviews
There are no reviews yet.